AU2297192A - Optically pure s(-) nadolol for treatment of cardiovascular disorders - Google Patents

Optically pure s(-) nadolol for treatment of cardiovascular disorders

Info

Publication number
AU2297192A
AU2297192A AU22971/92A AU2297192A AU2297192A AU 2297192 A AU2297192 A AU 2297192A AU 22971/92 A AU22971/92 A AU 22971/92A AU 2297192 A AU2297192 A AU 2297192A AU 2297192 A AU2297192 A AU 2297192A
Authority
AU
Australia
Prior art keywords
nadolol
treatment
optically pure
cardiovascular disorders
cardiovascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU22971/92A
Inventor
Timothy J Barberich
James W. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sunovion Pharmaceuticals Inc
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of AU2297192A publication Critical patent/AU2297192A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
AU22971/92A 1991-06-28 1992-06-25 Optically pure s(-) nadolol for treatment of cardiovascular disorders Abandoned AU2297192A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US722960 1985-04-12
US72296091A 1991-06-28 1991-06-28

Publications (1)

Publication Number Publication Date
AU2297192A true AU2297192A (en) 1993-01-25

Family

ID=24904188

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22971/92A Abandoned AU2297192A (en) 1991-06-28 1992-06-25 Optically pure s(-) nadolol for treatment of cardiovascular disorders

Country Status (2)

Country Link
AU (1) AU2297192A (en)
WO (1) WO1993000081A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
KR20060004959A (en) 2003-04-25 2006-01-16 노바카르디아, 인코포레이션 Method of improved diuresis in individuals with impaired renal function
WO2014165823A1 (en) * 2013-04-05 2014-10-09 Numedii, Inc. Treatment of gastrointestinal and other disorders
WO2023250334A1 (en) * 2022-06-21 2023-12-28 Curasen Therapeutics, Inc. Compositions and methods involving isolated compounds
WO2023250332A1 (en) * 2022-06-21 2023-12-28 Curasen Therapeutics, Inc. Compositions and methods involving isolated compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1464950A (en) * 1973-05-03 1977-02-16 Squibb & Sons Inc Naphthalene derivatives
EP0105996A1 (en) * 1982-10-15 1984-04-25 Merck & Co. Inc. Ophthalmic compositions for treating elevated intraocular pressure
DE3419130A1 (en) * 1984-05-23 1985-11-28 Bayer Ag, 5090 Leverkusen NIFEDIPINE COMBINATION PREPARATIONS AND METHOD FOR THEIR PRODUCTION

Also Published As

Publication number Publication date
WO1993000081A1 (en) 1993-01-07

Similar Documents

Publication Publication Date Title
AUPM864894A0 (en) Treatment of bowel-dependent neurological disorders
AU639192B2 (en) Treatment of water
IL121170A0 (en) Compositions for the treatment of dermatological disorders
AU2093392A (en) Treatment of congestive heart failure
AU6797094A (en) Cosmetic treatment of substrates
AU5965696A (en) Terpenoid-type quinones for treatment of diabetes
AU3007492A (en) Treatment of wastewater
AU7983691A (en) 1h-substituted-imidazo{4,5-d}pyridazine compounds for treatment of cardiovascular disorders
AU1115095A (en) Treatment of cellulose
AU2058697A (en) Treatment of sleep disorders
AU7903091A (en) N-substituted-1,2,4-triazolone compounds for treatment of cardiovascular disorders
AU8156094A (en) Methods of inhibiting breast disorders
AU7310896A (en) Use of nitroflavonoids for the treatment of anxiety
AU2806692A (en) Medicament for the treatment of anxiety
AU9024591A (en) Biphenylalkyl xanthine compounds for treatment of cardiovascular disorders
AU2297192A (en) Optically pure s(-) nadolol for treatment of cardiovascular disorders
AU5518694A (en) Treatment of a group of related disorders
AU8185491A (en) Treatment of disease
AU1807592A (en) New combination preparation for treatment of parkinson's disease
AU2882592A (en) Methods for treatment of hyperlipidemia using azaspiranes
ZA947912B (en) Treatment of medical disorders associated with free radical formation
AU1175692A (en) Effluent treatment
AU608865B2 (en) Treatment of cerebral disorders
AU2875092A (en) Methods for the treatment of hyperlipidemia using azaspiranes
AU1604692A (en) Treatment of longitudinally extending members